Cargando…

CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy

BACKGROUND: Doxorubicin-based chemotherapy is currently the most frequently used treatment for triple negative breast cancer (TNBC), yet the response rate is not high due to the lack of a biomarker allowing identification of responsive patients before the chemotherapy is initiated. We have demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denard, Bray, Jiang, Sharon, Peng, Yan, Ye, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090630/ https://www.ncbi.nlm.nih.gov/pubmed/30103710 http://dx.doi.org/10.1186/s12885-018-4724-8

Ejemplares similares

Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome
por: Denard, Bray, et al.
Publicado: (2015)

Doxorubicin blocks proliferation of cancer cells through proteolytic activation of CREB3L1
por: Denard, Bray, et al.
Publicado: (2012)

Sustained Induction of Collagen Synthesis by TGF-β Requires Regulated Intramembrane Proteolysis of CREB3L1
por: Chen, Qiuyue, et al.
Publicado: (2014)

Diet impacts triple‐negative breast cancer growth, metastatic potential, chemotherapy responsiveness, and doxorubicin‐mediated cardiac dysfunction
por: Ramirez, Manuel U., et al.
Publicado: (2022)

Identification of DNA methylation biomarkers with potential to predict response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Meyer, Braydon, et al.
Publicado: (2021)

Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer
por: Velenosi, Thomas J., et al.
Publicado: (2022)

Circulating non-coding RNA-biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
por: Ritter, Andrea, et al.
Publicado: (2019)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

EHD2 is a Predictive Biomarker of Chemotherapy Efficacy in Triple Negative Breast Carcinoma
por: Shen, Wei-Wei, et al.
Publicado: (2020)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer
por: Bawaneh, Alaa, et al.
Publicado: (2022)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
por: Chen, Dar-Ren, et al.
Publicado: (2014)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer
por: McKenna, Matthew T., et al.
Publicado: (2017)

Interfering MSN-NONO complex–activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer
por: Qin, Yuanyuan, et al.
Publicado: (2020)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
por: Krausz, Aimee E., et al.
Publicado: (2018)

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype
por: Yi, Seong Yoon, et al.
Publicado: (2010)

Predicting response and survival in chemotherapy-treated triple-negative breast cancer
por: Prat, A, et al.
Publicado: (2014)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Radosevic-Robin, Nina, et al.
Publicado: (2021)

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018)

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo
por: Lothstein, Leonard, et al.
Publicado: (2020)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy
por: Zhou, Jingyi, et al.
Publicado: (2023)

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
por: Zeng, Weiwei, et al.
Publicado: (2023)

Thrombospondin 2 is a Functional Predictive and Prognostic Biomarker for Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Lin, Yuxiang, et al.
Publicado: (2022)

Can MRI Biomarkers Predict Triple-Negative Breast Cancer?
por: Moffa, Giuliana, et al.
Publicado: (2020)

Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers
por: Ward, Alison K., et al.
Publicado: (2016)

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019)

Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity
por: Biswas, Dipsikha, et al.
Publicado: (2021)

PIM-1 kinase: a potential biomarker of triple-negative breast cancer
por: Chen, Jieying, et al.
Publicado: (2019)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer
por: Chen, Victor E., et al.
Publicado: (2017)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
por: Si, Yingnan, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Genomic Index of Sensitivity to Chemotherapy for Triple Negative Breast Cancer
por: C, Ahammad Sameer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_953ebqjbghbe4edhhno8v2rpri